---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-093906"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2025-07-03T23:59:59+00:00"
generated_at: "2026-05-18T09:28:37.329142+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics acquires early-stage life sciences company for 403k shares plus up to $89M milestones

## Summary
- Upfront consideration: 403,128 shares of BEAM common stock (~$6.86M based on $17.01 close).
- Earnout: up to $89M in development, clinical, and commercial milestones, payable in cash or stock at Beam's discretion.
- If milestones paid in stock, maximum issuable shares ~5.23M based on $17.01 closing price.
- Shares issued as unregistered securities under Section 4(a)(2) exemption.
- Target is an early-stage life sciences company; name not disclosed.

## SEC filing metadata
- accession: 0000950170-25-093906
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2025-07-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017025093906/0000950170-25-093906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017025093906/beam-20250701.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-093906
- JSON: https://secwatch.observer/filing/0000950170-25-093906.json
- Plain text: https://secwatch.observer/filing/0000950170-25-093906.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.